When and how should patients with multiple endocrine neoplasia type 1 be screened for thymic and bronchial carcinoid tumours?

Naykky Singh Ospina, Spyridoula Maraka, Victor Manuel Montori, Geoffrey B. Thompson, William Francis Young

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Patients with multiple endocrine neoplasia type 1 (MEN1) are commonly evaluated for clinical manifestations of this syndrome with the rationale that early diagnosis and adequate treatment will result in improved survival and quality of life. Thymic and bronchial carcinoid tumours are uncommon but important manifestations of MEN1. Current practice guidelines recommend evaluation with computed tomography or magnetic resonance imaging scan of the chest every 1-2 years to detect these neoplasms. However, the certainty that patients will be better off (increased survival or quality of life) as a result of this case detection strategy is based on evidence at moderate-high risk of bias that yields only imprecise results of indirect relevance to these patients. In order to improve the care that patients with MEN1 receive, co-ordinated efforts from different stakeholders are required so that large, prospective, multicentre studies evaluating patient important outcomes are carried out.

Original languageEnglish (US)
Pages (from-to)13-16
Number of pages4
JournalClinical Endocrinology
Volume84
Issue number1
DOIs
StatePublished - Jan 1 2016

Fingerprint

Multiple Endocrine Neoplasia Type 1
Carcinoid Tumor
Quality of Life
Survival
Practice Guidelines
Multicenter Studies
Early Diagnosis
Patient Care
Thorax
Tomography
Magnetic Resonance Imaging
Prospective Studies
Neoplasms

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

When and how should patients with multiple endocrine neoplasia type 1 be screened for thymic and bronchial carcinoid tumours? / Singh Ospina, Naykky; Maraka, Spyridoula; Montori, Victor Manuel; Thompson, Geoffrey B.; Young, William Francis.

In: Clinical Endocrinology, Vol. 84, No. 1, 01.01.2016, p. 13-16.

Research output: Contribution to journalArticle

@article{8b8e3f53a5dc4fce8f7a835482e61f51,
title = "When and how should patients with multiple endocrine neoplasia type 1 be screened for thymic and bronchial carcinoid tumours?",
abstract = "Patients with multiple endocrine neoplasia type 1 (MEN1) are commonly evaluated for clinical manifestations of this syndrome with the rationale that early diagnosis and adequate treatment will result in improved survival and quality of life. Thymic and bronchial carcinoid tumours are uncommon but important manifestations of MEN1. Current practice guidelines recommend evaluation with computed tomography or magnetic resonance imaging scan of the chest every 1-2 years to detect these neoplasms. However, the certainty that patients will be better off (increased survival or quality of life) as a result of this case detection strategy is based on evidence at moderate-high risk of bias that yields only imprecise results of indirect relevance to these patients. In order to improve the care that patients with MEN1 receive, co-ordinated efforts from different stakeholders are required so that large, prospective, multicentre studies evaluating patient important outcomes are carried out.",
author = "{Singh Ospina}, Naykky and Spyridoula Maraka and Montori, {Victor Manuel} and Thompson, {Geoffrey B.} and Young, {William Francis}",
year = "2016",
month = "1",
day = "1",
doi = "10.1111/cen.12972",
language = "English (US)",
volume = "84",
pages = "13--16",
journal = "Clinical Endocrinology",
issn = "0300-0664",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - When and how should patients with multiple endocrine neoplasia type 1 be screened for thymic and bronchial carcinoid tumours?

AU - Singh Ospina, Naykky

AU - Maraka, Spyridoula

AU - Montori, Victor Manuel

AU - Thompson, Geoffrey B.

AU - Young, William Francis

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Patients with multiple endocrine neoplasia type 1 (MEN1) are commonly evaluated for clinical manifestations of this syndrome with the rationale that early diagnosis and adequate treatment will result in improved survival and quality of life. Thymic and bronchial carcinoid tumours are uncommon but important manifestations of MEN1. Current practice guidelines recommend evaluation with computed tomography or magnetic resonance imaging scan of the chest every 1-2 years to detect these neoplasms. However, the certainty that patients will be better off (increased survival or quality of life) as a result of this case detection strategy is based on evidence at moderate-high risk of bias that yields only imprecise results of indirect relevance to these patients. In order to improve the care that patients with MEN1 receive, co-ordinated efforts from different stakeholders are required so that large, prospective, multicentre studies evaluating patient important outcomes are carried out.

AB - Patients with multiple endocrine neoplasia type 1 (MEN1) are commonly evaluated for clinical manifestations of this syndrome with the rationale that early diagnosis and adequate treatment will result in improved survival and quality of life. Thymic and bronchial carcinoid tumours are uncommon but important manifestations of MEN1. Current practice guidelines recommend evaluation with computed tomography or magnetic resonance imaging scan of the chest every 1-2 years to detect these neoplasms. However, the certainty that patients will be better off (increased survival or quality of life) as a result of this case detection strategy is based on evidence at moderate-high risk of bias that yields only imprecise results of indirect relevance to these patients. In order to improve the care that patients with MEN1 receive, co-ordinated efforts from different stakeholders are required so that large, prospective, multicentre studies evaluating patient important outcomes are carried out.

UR - http://www.scopus.com/inward/record.url?scp=84956600234&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956600234&partnerID=8YFLogxK

U2 - 10.1111/cen.12972

DO - 10.1111/cen.12972

M3 - Article

VL - 84

SP - 13

EP - 16

JO - Clinical Endocrinology

JF - Clinical Endocrinology

SN - 0300-0664

IS - 1

ER -